Compare uniQure N.V. Ordinary Shares (QURE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Twist Bioscience Corp — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Twist Bioscience Corp trades at $145.29 (market cap $10.03B). The key difference: Twist Bioscience Corp is far larger — about 6.8× uniQure N.V. Ordinary Shares's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Twist Bioscience Corp for 27 Days on average.
| QURE | TWST | |
|---|---|---|
Market Cap | $1.48B | $10.03B |
Volume | 2,488,780 | 1,528,940 |
Sector | Health | Health |
52-Week High | $70.59 | $205.00 |
52-Week Low | $9.03 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $728.62M | $9.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $148.16, down 2.44% today, with a bullish technical signal but negative earnings trends. Recent news highlights its role in Eli Lilly's AI drug discovery platform, driving investor optimism. Revenue growth is strong, reaching $376.57M in 2025, but net losses persist, with a margin of -20.63%. The stock faces resistance near $154, with support at $146.
Outlook is mixed: analyst consensus is bullish with a $153.70 price target, but profitability challenges and cash flow deficits pose risks. The AI collaboration offers growth potential, yet execution and margin improvement are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
